Biotechnology

Abivax SA

Abivax SA to Release FY2026 Q1 Earnings on May 25 Pre-Market EST, Forecast Revenue USD 401.26K, EPS USD -0.9013

JPMorgan Increases Holdings in Abivax to 5.52%

Abivax Prices $45 Million Follow-on Offering and Repurchases Warrants

JPMorgan Cuts Stake in Abivax to 4.96%

Abivax Shareholders Vote on Issuing Ordinary Share Warrants

JPMorgan Acquires 5.23% Stake in Abivax

Abivax's oral obefazimod reaches primary endpoint in Phase III trials

UBS Reduced Its Stake in Abivax to 4.11%

Abivax Reports 2025 Performance and Confirms 3rd Phase Timeline for Ulcerative Colitis

Abivax SA released FY2025 Q4 earnings on March 23 During-Market EST, actual revenue USD 2.248 M (forecast USD 1.581 M), actual EPS USD -1.2309 (forecast USD -1.4426)

Abivax SA released FY2025 earnings on March 23 During-Market EST, actual revenue USD 5.266 M (forecast USD 6.565 M), actual EPS USD -5.5699 (forecast USD -4.4921)

Abivax SA to Release FY2025 Earnings on March 23 During-Market EST, Forecast Revenue USD 6.583 M, EPS USD -4.4921

Abivax Denies AstraZeneca Acquisition Rumors

Abivax Announces Anti-Fibrotic Effects of Obefazimod at ECCO 2026

Investors Express Bearish Sentiment on Abivax

Truist Financial Analyst Maintains Buy Rating on Abivax SA

Morgan Stanley Raises Abivax Price Target to $145

French Treasury clarifies no investment requests from Eli Lilly for Abivax

Kepler Capital Maintains Buy Rating on Abivax SA

Morgan Stanley Raises Abivax's Target Price to $145

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

Earning Release Date

财报预告

FY2026 Q1 Earning Release 2026.05.25 (EST) Pre-Market

ABVX

LABU

ARKG

Abivax has disclosed the repurchase of royalty certificates along with the pricing details of its $45 million (€38.5 million) offering of American Depositary Shares.

Unusual Whales

iShares Biotechnology ETF

VG Health

SPDR S&P Biotech

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

iShares Global Healthcare

iShares US Pharma

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax SA has announced the repurchase of royalty certificates and the pricing of a $45 million offering of American Depositary Shares (ADSs). The offering will consist of 403,347 ordinary shares priced at $111.57 per ADS. The company aims to strengthen its balance sheet and reduce legacy obligations. The purchase agreement includes a total price of $90 million for the royalty certificates, with $45 million paid in cash and the remaining $45 million as an interest-free vendor's loan. The offering is expected to close around May 7, 2026, with a dilution of approximately 0.5% in share capital.

StockTitan

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares | ABVX Stock News

Total Clarity Wealth Management Inc. acquired 9,245 shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) valued at approximately $1.25 million during the fourth quarter. Other institutional investors also increased their stakes in Abivax, with notable increases from EverSource Wealth Advisors and Bank of America Corp DE. Abivax's stock opened at $117.38, with a market cap of $9.31 billion and a price-to-earnings ratio of -21.86. Analysts have mixed ratings on the stock, with an average target price of $137.15.

Market Beat

First Horizon

Bank of America

Citigroup

Oppenheimer

Jefferies Financial

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Total Clarity Wealth Management Inc. Acquires Shares of 9,245 Abivax SA Sponsored ADR $ABVX

China Universal Asset Management Co. Ltd. has acquired 11,619 shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) valued at approximately $1.57 million, as reported in its recent 13F filing. Other institutional investors have also increased their stakes in Abivax. The stock has a market cap of $9.08 billion and a PE ratio of -21.33. Analysts have mixed ratings on Abivax, with a consensus rating of "Moderate Buy" and a price target of $137.15. Abivax focuses on developing therapies for chronic inflammatory diseases and viral infections.

Federated Hermes

Barclays

China Universal Asset Management Co. Ltd. Purchases Shares of 11,619 Abivax SA Sponsored ADR $ABVX

Wall Street Zen upgraded Abivax (NASDAQ:ABVX) from a "sell" to a "hold" rating. Other firms like Citigroup and Morgan Stanley have also provided positive ratings, with Morgan Stanley raising the price target to $145. Abivax's stock is currently down 1.9%, trading at $120.16, with a market cap of $9.53 billion. The company reported a quarterly EPS of ($1.20) and anticipates a -2.83 EPS for the current year. Institutional investors hold 47.91% of the stock.

Morgan Stanley

Bank of Hawaii

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF HAWAII CORPORATION DEP SHS REPSTG 1/40TH INT SH NON CUM PER

BANK OF HAWAII CORP 4.375% DEP SHS REPSTG 1/40TH PFD SER A

Abivax (NASDAQ:ABVX) Upgraded to "Hold" at Wall Street Zen

Abivax's stock has dropped over 10% this year, despite promising developments in its lead candidate, obefazimod, for ulcerative colitis. While the drug shows potential, especially after a successful phase 3 study, risks remain, particularly regarding the upcoming maintenance study results. Investors should weigh the high market cap against the company's lack of revenue and consider their risk tolerance before investing. Analysts suggest there are safer biotech options available.

nasdaq

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

ABIVAX Société Anonyme's stock has recently pulled back, closing at €89.20 after an 18.5% decline over the past week. Despite this, the company has shown strong long-term gains. A Discounted Cash Flow analysis suggests the stock is undervalued by 87.0%, with an estimated intrinsic value of €685.04 per share. However, its Price-to-Book ratio of 15.52x is significantly higher than industry averages, indicating a richer valuation compared to peers. Investors are encouraged to consider different valuation methods and narratives for a comprehensive understanding of the company's worth.

Simplywall

Is It Time To Reassess Abivax (ENXTPA:ABVX) After The Recent Share Price Pullback

Abivax SA(ABVX.US)